Emcure Pharmaceuticals Limited (BOM:544210)
India
· Delayed Price · Currency is INR 991.60
-4.40 (-0.44%)
At close: Feb 20, 2025
Emcure Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | 75,511 | 66,583 | 59,858 | 58,554 | 50,335 | 50,486 | Upgrade
|
| Revenue Growth (YoY) | 16.45% | 11.23% | 2.23% | 16.33% | -0.30% | 7.02% | Upgrade
|
| Cost of Revenue | 29,858 | 25,357 | 23,185 | 22,864 | 19,269 | 20,748 | Upgrade
|
| Gross Profit | 45,653 | 41,225 | 36,673 | 35,690 | 31,065 | 29,737 | Upgrade
|
| Selling, General & Admin | 16,974 | 15,780 | 13,069 | 11,805 | 10,272 | 12,941 | Upgrade
|
| Other Operating Expenses | 14,391 | 12,762 | 11,597 | 10,562 | 8,606 | 9,621 | Upgrade
|
| Operating Expenses | 35,529 | 32,052 | 27,459 | 24,835 | 21,402 | 25,825 | Upgrade
|
| Operating Income | 10,124 | 9,173 | 9,214 | 10,855 | 9,663 | 3,912 | Upgrade
|
| Interest Expense | -1,600 | -1,949 | -1,629 | -1,325 | -1,140 | -2,046 | Upgrade
|
| Interest & Investment Income | 207.59 | 207.59 | 118.34 | 101.97 | 69.87 | 21.86 | Upgrade
|
| Currency Exchange Gain (Loss) | -160.03 | 48.12 | -29.88 | 222.54 | 30.33 | 397.08 | Upgrade
|
| Other Non Operating Income (Expenses) | 108.27 | -205.93 | -137.55 | -124.92 | -66.8 | -115.62 | Upgrade
|
| EBT Excluding Unusual Items | 8,681 | 7,274 | 7,536 | 9,730 | 8,557 | 2,170 | Upgrade
|
| Merger & Restructuring Charges | -99.31 | -99.31 | - | - | - | - | Upgrade
|
| Impairment of Goodwill | - | - | - | - | - | -39.83 | Upgrade
|
| Gain (Loss) on Sale of Investments | 25.32 | 25.32 | 1.21 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 71.92 | 71.92 | -3.33 | -4.08 | 4.29 | -41.57 | Upgrade
|
| Other Unusual Items | 97.94 | - | -61.46 | - | -153.82 | -1,035 | Upgrade
|
| Pretax Income | 8,776 | 7,272 | 7,472 | 9,725 | 8,407 | 1,053 | Upgrade
|
| Income Tax Expense | 2,464 | 1,997 | 1,854 | 2,700 | 2,334 | 47.25 | Upgrade
|
| Earnings From Continuing Operations | 6,312 | 5,276 | 5,618 | 7,026 | 6,073 | 1,006 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | -1,887 | - | Upgrade
|
| Net Income to Company | 6,312 | 5,276 | 5,618 | 7,026 | 4,186 | 1,006 | Upgrade
|
| Minority Interest in Earnings | -237.04 | -293.92 | -298.26 | -403.56 | -264.47 | -170.03 | Upgrade
|
| Net Income | 6,075 | 4,982 | 5,320 | 6,622 | 3,921 | 836.07 | Upgrade
|
| Net Income to Common | 6,075 | 4,982 | 5,320 | 6,622 | 3,921 | 836.07 | Upgrade
|
| Net Income Growth | 12.55% | -6.36% | -19.66% | 68.87% | 369.04% | -55.83% | Upgrade
|
| Shares Outstanding (Basic) | 185 | 181 | 181 | 181 | 181 | 181 | Upgrade
|
| Shares Outstanding (Diluted) | 185 | 181 | 181 | 181 | 181 | 181 | Upgrade
|
| Shares Change (YoY) | 2.25% | 0.01% | - | - | - | - | Upgrade
|
| EPS (Basic) | 32.86 | 27.54 | 29.42 | 36.62 | 21.68 | 4.62 | Upgrade
|
| EPS (Diluted) | 32.85 | 27.54 | 29.42 | 36.62 | 21.68 | 4.62 | Upgrade
|
| EPS Growth | 10.07% | -6.38% | -19.66% | 68.90% | 369.23% | -55.86% | Upgrade
|
| Free Cash Flow | - | 8,215 | 3,563 | 3,900 | 5,790 | 3,850 | Upgrade
|
| Free Cash Flow Per Share | - | 45.42 | 19.70 | 21.56 | 32.02 | 21.29 | Upgrade
|
| Dividend Per Share | - | - | 2.000 | 3.000 | 1.000 | 2.500 | Upgrade
|
| Dividend Growth | - | - | -33.33% | 200.00% | -60.00% | -44.44% | Upgrade
|
| Gross Margin | 60.46% | 61.92% | 61.27% | 60.95% | 61.72% | 58.90% | Upgrade
|
| Operating Margin | 13.41% | 13.78% | 15.39% | 18.54% | 19.20% | 7.75% | Upgrade
|
| Profit Margin | 8.05% | 7.48% | 8.89% | 11.31% | 7.79% | 1.66% | Upgrade
|
| Free Cash Flow Margin | - | 12.34% | 5.95% | 6.66% | 11.50% | 7.63% | Upgrade
|
| EBITDA | 13,056 | 11,805 | 11,446 | 12,911 | 12,419 | 6,657 | Upgrade
|
| EBITDA Margin | 17.29% | 17.73% | 19.12% | 22.05% | 24.67% | 13.19% | Upgrade
|
| D&A For EBITDA | 2,932 | 2,632 | 2,232 | 2,057 | 2,756 | 2,745 | Upgrade
|
| EBIT | 10,124 | 9,173 | 9,214 | 10,855 | 9,663 | 3,912 | Upgrade
|
| EBIT Margin | 13.41% | 13.78% | 15.39% | 18.54% | 19.20% | 7.75% | Upgrade
|
| Effective Tax Rate | 28.07% | 27.45% | 24.81% | 27.76% | 27.77% | 4.49% | Upgrade
|
| Revenue as Reported | 76,395 | 67,152 | 60,317 | 59,189 | 50,674 | 51,309 | Upgrade
|
| Advertising Expenses | - | 2,788 | 1,828 | 1,633 | 1,220 | 1,848 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.